Universität zu Köln

Verboon, Christine ORCID: 0000-0003-2229-8154, Doets, Alex Y., Galassi, Giuliana, Davidson, Amy, Waheed, Waqar, Pereon, Yann, Shahrizaila, Nortina, Kusunoki, Susumu, Lehmann, Helmar C., Harbo, Thomas, Monges, Soledad, Van den Bergh, Peter, Willison, Hugh J., Cornblath, David R., Jacobs, Bart C., Van Dijk, G. W., Van der Ree, T., Van Koningsveld, R., Valzania, F., Varrato, J. D., Vermeij, F. H., Verschuuren, J., Visser, L. H., Vytopil, M. V., Wilken, M., Wilkerson, C., Wirtz, P. W., Yamagishi, Y., Zhou, L. and Zivkovic, S. A. (2019). Current treatment practice of Guillain-Barre syndrome. Neurology, 93 (1). S. E59 - 18. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1526-632X

Full text not available from this repository.

Abstract

Objective To define the current treatment practice of Guillain-Barre syndrome (GBS). Methods The study was based on prospective observational data from the first 1,300 patients included in the International GBS Outcome Study. We described the treatment practice of GBS in general, and for (1) severe forms (unable to walk independently), (2) no recovery after initial treatment, (3) treatment-related fluctuations, (4) mild forms (able to walk independently), and (5) variant forms including Miller Fisher syndrome, taking patient characteristics and hospital type into account. Results We excluded 88 (7%) patients because of missing data, protocol violation, or alternative diagnosis. Patients from Bangladesh (n = 189, 15%) were described separately because 83% were not treated. IV immunoglobulin (IVIg), plasma exchange (PE), or other immunotherapy was provided in 941 (92%) of the remaining 1,023 patients, including patients with severe GBS (724/743, 97%), mild GBS (126/168, 75%), Miller Fisher syndrome (53/70, 76%), and other variants (33/40, 83%). Of 235 (32%) patients who did not improve after their initial treatment, 82 (35%) received a second immune modulatory treatment. A treatment-related fluctuation was observed in 53 (5%) of 1,023 patients, of whom 36 (68%) were re-treated with IVIg or PE. Conclusions In current practice, patients with mild and variant forms of GBS, or with treatment-related fluctuations and treatment failures, are frequently treated, even in absence of trial data to support this choice. The variability in treatment practice can be explained in part by the lack of evidence and guidelines for effective treatment in these situations.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Verboon, Christine UNSPECIFIED orcid.org/0000-0003-2229-8154 UNSPECIFIED Doets, Alex Y. UNSPECIFIED UNSPECIFIED UNSPECIFIED Galassi, Giuliana UNSPECIFIED UNSPECIFIED UNSPECIFIED Davidson, Amy UNSPECIFIED UNSPECIFIED UNSPECIFIED Waheed, Waqar UNSPECIFIED UNSPECIFIED UNSPECIFIED Pereon, Yann UNSPECIFIED UNSPECIFIED UNSPECIFIED Shahrizaila, Nortina UNSPECIFIED UNSPECIFIED UNSPECIFIED Kusunoki, Susumu UNSPECIFIED UNSPECIFIED UNSPECIFIED Lehmann, Helmar C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Harbo, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Monges, Soledad UNSPECIFIED UNSPECIFIED UNSPECIFIED Van den Bergh, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Willison, Hugh J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornblath, David R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Jacobs, Bart C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Van Dijk, G. W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Van der Ree, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Van Koningsveld, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Valzania, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Varrato, J. D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Vermeij, F. H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Verschuuren, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Visser, L. H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Vytopil, M. V. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wilken, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wilkerson, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wirtz, P. W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Yamagishi, Y. UNSPECIFIED UNSPECIFIED UNSPECIFIED Zhou, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Zivkovic, S. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-135657
DOI:	10.1212/WNL.0000000000007719
Journal or Publication Title:	Neurology
Volume:	93
Number:	1
Page Range:	S. E59 - 18
Date:	2019
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1526-632X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INTRAVENOUS IMMUNOGLOBULIN; PLASMA-EXCHANGE; RANDOMIZED-TRIAL Multiple languages Clinical Neurology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/13565